Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.

Cell Death & Disease
Yu LiuTianwu Yang

Abstract

Bevacizumab in neoadjuvant therapy provides a new hope of improved survival for patients with triple-negative breast cancer (TNBC) by targeting vascular endothelial growth factor in combination with chemotherapy, but curative effect is limited by bevacizumab's continuous use while mechanisms remain incompletely understood. More and more researches reported that tumor-associated macrophages mediate resistance to chemotherapy and radiotherapy in various tumors. Here we developed a TNBC model resistant to bevacizumab under bevacizumab continuous administration. It was found that proportion of a specific subset of tumor-associated macrophages characterized as M2b (CD11b+ CD86high IL10high) increased and responsible for acquired resistance to bevacizumab. Then, we showed that RAW264.7 macrophages could be polarized to M2b subtype on simultaneous exposure to bevacizumab and TLR4 ligands as occurs in the context of continuous bevacizumab treatment. Concordantly, in TLR4-deleted C57BL/10ScNJNju (TLR4lps-del) mut/mut mice with bevacizumab treatment model, it was verified that the M2b macrophage could be induced by Fc gamma receptor-TLR4 cross-talk. In MDA-MB-231-resistant tumor-bearing mice, the content of TNFα in serum kept going up co...Continue Reading

References

Apr 28, 2009·Gene·Douglas A JohnstonChristopher C W Hughes
Jun 9, 2009·PLoS Pathogens·Daniel RittirschPeter A Ward
Jan 21, 2010·British Journal of Cancer·Y Wu, B P Zhou
Apr 30, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Weijuan ZhangSidong Xiong
Sep 22, 2010·Nature Immunology·Subhra K Biswas, Alberto Mantovani
Jun 15, 2011·Proceedings of the National Academy of Sciences of the United States of America·Tiziana SchioppaFrances R Balkwill
Jan 27, 2012·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arman JahangiriManish K Aghi
Sep 10, 2013·Angiogenesis·Nadine JettenMarjo M P C Donners
Aug 16, 2014·Cancers·Theerawut ChanmeeNaoki Itano
Oct 13, 2014·Molecular Oncology·Viola BigattoCarla Boccaccio
Aug 4, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Rui-Xian LiuDong-Ming Kuang
Dec 5, 2015·Nature Communications·Atsushi MitsuhashiYasuhiko Nishioka
Aug 27, 2016·Archives of Pharmacal Research·Inmoo Rhee
Nov 1, 2016·Nature·Megan M KanedaJudith A Varner
Jul 12, 2017·The Journal of Allergy and Clinical Immunology·Heng WangPeisong Gao
Aug 18, 2017·International Journal of Molecular Sciences·Deok-Hoon KongSukmook Lee
Sep 9, 2017·Cell·Yenkel Grinberg-BleyerSankar Ghosh
Aug 15, 2019·Cancer Biotherapy & Radiopharmaceuticals·Sara RamezaniShahrokh Yousefzadeh Chabok

❮ Previous
Next ❯

Citations

Aug 28, 2021·International Journal of Molecular Sciences·Thomas BenootCleo Goyvaerts

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
fluorescence-activated cell measuring
flow cytometry
xenograft
enzyme-linked immunosorbent assay
xenografts
ELISA

Software Mentioned

FlowJo

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

The Oncologist
Filis Kazazi-HyseniJan H M Schellens
Nihon rinsho. Japanese journal of clinical medicine
Naoyuki Ohe, Toru Iwama
Nature Reviews. Drug Discovery
Mohamed MuhsinPeter Kirkpatrick
Revue de l'infirmière
Corinne Taéron
© 2021 Meta ULC. All rights reserved